RxDoctor Payments Data

Roberto Mauri, MD

Internal Medicine · Elmira, NYNPI 1306885306

Payments from drug & device makers

$531in general payments, 2019–2025

Across 27 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$188
  • Novo Nordisk$62
  • Pfizer$60
  • Johnson & Johnson$52
  • Kowa Pharmaceuticals America, Inc.$47
  • Merck$38
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$52098%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$531 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$135,659
Medicare patients
419
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide160$177,324
EliquisApixaban168$155,108
XareltoRivaroxaban79$74,510
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$61,556
JardianceEmpagliflozin55$47,365
RybelsusSemaglutide13$26,505
FarxigaDapagliflozin Propanediol18$24,162
TradjentaLinagliptin20$21,558
LinzessLinaclotide27$18,020
JanuviaSitagliptin Phosphate20$17,713
EntrestoSacubitril/Valsartan11$14,329
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$13,438
TresibaInsulin Degludec26$10,150
LivaloPitavastatin Calcium14$9,889
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$9,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba$62$213,978199 claims
PfizerEliquis$60$155,108168 claims
Johnson & JohnsonXarelto$52$74,51079 claims
GSKTrelegy Ellipta, Breo Ellipta$33$71,06489 claims
Boehringer IngelheimJardiance, Tradjenta$13$68,92375 claims
MerckJanuvia, Lagevrio (Eua)$38$24,17335 claims
AstraZenecaFarxiga$12$24,16218 claims
AbbVieLinzess$188$18,02027 claims
Kowa Pharmaceuticals America, Inc.Livalo$47$9,88914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →